Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for TransMedics (TMDX) over the last 8 years, with Q3 2025 value amounting to $54.6 million.

  • TransMedics' Non-Current Debt fell 791.14% to $54.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.6 million, marking a year-over-year decrease of 791.14%. This contributed to the annual value of $59.4 million for FY2024, which is 52.15% up from last year.
  • According to the latest figures from Q3 2025, TransMedics' Non-Current Debt is $54.6 million, which was down 791.14% from $59.5 million recorded in Q2 2025.
  • In the past 5 years, TransMedics' Non-Current Debt ranged from a high of $59.5 million in Q2 2025 and a low of $34.8 million during Q1 2021
  • In the last 5 years, TransMedics' Non-Current Debt had a median value of $58.8 million in 2023 and averaged $51.3 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 6698.04% in 2022, then tumbled by 791.14% in 2025.
  • Quarter analysis of 5 years shows TransMedics' Non-Current Debt stood at $35.2 million in 2021, then soared by 66.76% to $58.7 million in 2022, then rose by 0.63% to $59.1 million in 2023, then rose by 0.52% to $59.4 million in 2024, then decreased by 8.03% to $54.6 million in 2025.
  • Its Non-Current Debt stands at $54.6 million for Q3 2025, versus $59.5 million for Q2 2025 and $59.4 million for Q1 2025.